Share on StockTwits

XOMA Corp (NASDAQ:XOMA) VP Patrick J. Md Phd Scannon unloaded 5,000 shares of XOMA Corp stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $4.68, for a total value of $23,400.00. Following the transaction, the vice president now directly owns 86,546 shares of the company’s stock, valued at approximately $405,035. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of XOMA Corp (NASDAQ:XOMA) opened at 4.71 on Friday. XOMA Corp has a 52 week low of $3.42 and a 52 week high of $9.57. The stock’s 50-day moving average is $4.39 and its 200-day moving average is $5.81. The company’s market cap is $503.5 million.

XOMA Corp (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.06. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $7.40 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. The company’s quarterly revenue was down 63.9% on a year-over-year basis. On average, analysts predict that XOMA Corp will post $-0.65 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on XOMA shares. Analysts at Wedbush raised their price target on shares of XOMA Corp to $14.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Analysts at MLV & Co
upgraded shares of XOMA Corp from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. They now have a $7.00 price target on the stock. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. XOMA Corp has a consensus rating of “Buy” and a consensus price target of $9.11.

XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.